Xencor (NASDAQ:XNCR) Shares Pass Below 200 Day Moving Average of $21.49

Xencor, Inc. (NASDAQ:XNCR)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $21.49 and traded as low as $19.30. Xencor shares last traded at $19.80, with a volume of 2,260,022 shares traded.

Analysts Set New Price Targets

Several research firms have recently weighed in on XNCR. BTIG Research reduced their price objective on Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, April 16th. Wedbush reissued an “outperform” rating and issued a $34.00 price objective (down previously from $36.00) on shares of Xencor in a research report on Thursday, June 13th. StockNews.com upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research note on Saturday, March 9th. Piper Sandler restated a “neutral” rating and set a $24.00 price objective (down from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. Finally, Royal Bank of Canada decreased their price objective on Xencor from $32.00 to $31.00 and set an “outperform” rating for the company in a report on Friday, June 14th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.38.

Xencor Trading Up 2.2 %

The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -9.04 and a beta of 0.82. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.08 and a quick ratio of 7.08. The business’s 50-day moving average price is $21.74 and its two-hundred day moving average price is $21.49.

Xencor (NASDAQ:XNCR) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.28). Xencor had a negative net margin of 82.23% and a negative return on equity of 20.29%. The company had revenue of $12.80 million for the quarter, compared to the consensus estimate of $23.07 million. During the same quarter in the previous year, the company posted ($1.02) earnings per share. The business’s revenue was down 32.3% compared to the same quarter last year. Research analysts predict that Xencor, Inc. will post -3.5 earnings per share for the current year.

Institutional Trading of Xencor

Several large investors have recently made changes to their positions in the company. Primecap Management Co. CA grew its position in Xencor by 8.8% in the fourth quarter. Primecap Management Co. CA now owns 8,901,607 shares of the biopharmaceutical company’s stock valued at $188,981,000 after acquiring an additional 717,401 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Xencor by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock valued at $155,154,000 after purchasing an additional 243,793 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Xencor by 9.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after purchasing an additional 335,881 shares in the last quarter. Armistice Capital LLC lifted its stake in Xencor by 1.5% in the 4th quarter. Armistice Capital LLC now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $31,845,000 after purchasing an additional 22,000 shares during the last quarter. Finally, Darwin Global Management Ltd. bought a new position in Xencor in the 1st quarter valued at approximately $24,557,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.